RetinalGenix Technologies Inc. [OTCQB: RTGN] ('RetinalGenix” or the 'Company”), a company developing ultra-high-resolution ...

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice ...

RetinaDA unites six public fundus sets into a 512 × 512 macula-centered benchmark with built-in domain gaps, enabling ...

Until now, it has been difficult to maintain retinal ganglion cells deep inside organoids over extended periods. The supply of nutrients and oxygen in ...

Just a few years ago, the lion’s share of investment in new ophthalmic drugs was for topical antibiotics.The target market ...

Skincare enthusiasts are buzzing about Retinal, a potent Vitamin A derivative that's faster and more effective than ...

At Appasamy Associates, empowering vision starts with awareness. Diabetic eye health demands timely attention, and retinal ...

Researchers from the Optics Group at the Universitat Jaume I in Castellón have managed to correct in real time problems ...

Panelists discuss how aflibercept 8 mg maintains a safety profile similar to 2 mg and how workflow, systemic risk, and ...

Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...

About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...